novo nordisk oral semaglutide fda approval has announced that the has approved the Wegovy® pill (once-daily 25 mg) as the first ever oral GLP-1 receptor agonist therapy for chronic weight management in adults FDA approval for Wegovy pill

Urinary tract infections (UTIs) are not listed as a common side effect of Ozempic in FDA labeling, yet patients and healthcare providers have reported this concern during GLP-1 therapy

The mechanisms that caused initial weight gain remain present, and appetite typically returns to pre-treatment levels within weeks of discontinuation

These are the same formulas used in laboratory and clinical research settings

Other early side effects may include: Injection site reactions (redness, itching, bruising) usually mild and transient Headache Common Most gastrointestinal side effects are mild to moderate in severity and tend to diminish as the body adapts to the medication